Roche dumps hep C development deal with Ligand

Roche is dumping another development pact. This time the Swiss pharma giant is dropping a deal to develop new hepatitis C drugs with Ligand Pharmaceuticals ($LGNDD), according to the UK biotech.

The two companies struck a deal back in 2008 to use Metabasis' liver-targeting technology to find a new approach to treating the viral disease. Reuters reports that Ligand filed regulatory paperwork indicating that Roche's termination includes its commitment not to develop similar compounds in the next 10 years.

There's no word from either company what prompted the move, but Roche has launched a wide-ranging restructuring that recently spurred the company to write off $500 million in R&D work regarding RNAi programs.

Ligand says it first heard of Roche's decision on Friday. The developer earned a $6.5 million milestone from Roche last spring after the pharma company pushed RG7348 into Phase I. Ligand acquired its technology partner Metabasis at the beginning of this year. The struggling California company sold for only $3.2 million.

- here's the story from Reuters

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.